A Study Evaluating TIL therapy (LN-144) With Opdivo (Nivolumab) For The Treatment Of Patients With Metastatic Melanoma.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Lifileucel (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 14 Mar 2017 New trial record